Type 2 diabetic nephrology
Conditions
Interventions
oral administration of Linagliptin (5mg/day) once in the morning
oral administration of Teneligliptin (20mg/day) once in the morning
Sponsors
Nagoya City University Graduate School of Medical Sciences Department of Cardio-Renal Medicine and Hypertension
Nagoya City East Medical Center Asahi Rousai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) type 2 diabetes mellitus 2) age 20 or more years, regardless of gender 3) outpatient and inpatient 4) target HbA1c <7.0% is not achieved after approximately 3 months treatment with metformin 5) documented informed consent
Exclusion criteria
Exclusion criteria: 1) GFR <30 30ml/min/1.73m2 or undergoing renal replacement therapy 2) severe ketosis, diabetic coma or pre-come 3) conditions with serious infection, perioperative period, and severe trauma 4) presence/possibility for pregnancy/lactation 5) GOT >100, or GPT >85 6) current treatment with insulin 7) any reason for ineligibility suggested by the attending doctor (history of allergic reaction to study medication)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in night/day ratio of blood pressure during 8 week treatment with DPP4 inhibitors (week 8) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) increase in daytime urinary sodium excretion (day2) 2) decrease in glomerulotubular Na balance (SNa x GFR, tNa) 3) constancy of daily urinary Na excretion 4) sympathetic and parasympathetic nerve activity (assessed by heart rate variability) 5) HbA1c 6) urine anion gap, serum bicarbonate concentration | — |
Countries
Japan
Contacts
Public ContactMiyoko Suzuki
Nagoya City University Hospital Clinical Research Management Center
Outcome results
None listed